VolitionRX (VNRX) Stock Price, News & Analysis

Company Overview

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions. These assays are undergoing clinical validation in collaboration with leading research institutions, with the goal of establishing robust performance metrics for large-scale screening programs. VolitionRX continues to expand its pipeline by exploring new indications and refining assay sensitivity and specificity through ongoing R&D activities.

Headquartered in Belgium, VolitionRX maintains a global presence with subsidiary operations and strategic partnerships across the United States, Europe and Asia. Its management team brings together expertise in molecular diagnostics, regulatory affairs and commercial development, positioning the company to navigate clinical trials, regulatory submissions and market entry. Through alliances with academic centers, contract research organizations and healthcare providers, VolitionRX is working to scale manufacturing, streamline laboratory workflows and accelerate the adoption of its blood-based diagnostic tests worldwide.

Key Stats

• Today's Range: $2.49 to $2.81
• 50-Day Range: $2.00 to $4.11
• 52-Week Range: $1.91 to $18.80
• Volume: 174,896 shs
• Average Volume: 433,674 shs
• Market Capitalization: $22.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $46.67
• Consensus Rating: Moderate Buy

VolitionRX Stock Analysis - MarketRank™

VolitionRX scored higher than 56% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

VolitionRX has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 1 strong buy rating, 1 buy rating, 3 hold ratings, and no sell ratings.

Upside Potential

VolitionRX has a consensus price target of $46.67, representing about 1,609.4% upside from its current price of $2.73.

Amount of Analyst Coverage

VolitionRX has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of VolitionRX is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of VolitionRX is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.64% of the float of VolitionRX has been sold short.

Short Interest Ratio / Days to Cover

VolitionRX has a short interest ratio ("days to cover") of 1.39, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in VolitionRX has recently decreased by 96.20%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

VolitionRX does not currently pay a dividend.

Dividend Growth

VolitionRX does not have a long track record of dividend growth.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: -0.41

News Sentiment

VolitionRX has a news sentiment score of -0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for VolitionRX this week, compared to 2 articles on an average week.

Search Interest

Only 10 people have searched for VNRX on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.

MarketBeat Follows

5 people have added VolitionRX to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, VolitionRX insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.70% of the stock of VolitionRX is held by insiders.

Percentage Held by Institutions

8.09% of the stock of VolitionRX is held by institutions.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 5/21/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:VNRX
• Previous Symbol: NYSEMKT:VNRX
• CIK: 93314
• Web: www.volitionrx.com
• Phone: (646) 650-1351
• Fax: 65 32 8172 5651
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Price Target for VolitionRX: $46.67
• High Price Target: $60.00
• Low Price Target: $20.00
• Potential Upside/Downside: +1,631.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.56)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$23.36 million
• Net Margins: -997.49%
• Pretax Margin: -1,002.84%
• Return on Equity: N/A
• Return on Assets: -289.87%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.33
• Quick Ratio: 0.17

Sales & Book Value

• Annual Sales: $1.73 million
• Price / Sales: 12.98
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($4.00) per share
• Price / Book: -0.67

Miscellaneous

• Outstanding Shares: 8,330,000
• Free Float: 7,605,000
• Market Cap: $22.45 million
• Optionable: Not Optionable
• Beta: 1.03